On this episode of Mushroom Talk, we have Tim Schlidt joining us to chat about the role that venture capital plays in the psychedelic space. We dive deep into what he looks for in a founder and company when he is investing, and his story coming out of the psychedelic closet. One important note that we discuss are his thoughts on the corporatization of plant medicine, specifically the role of patents. Tim is a mover and shaker in the VC Psychedelic space bringing us a ton of knowledge, wisdom, and guidance on finance and psychedelics.

About Tim:

Years ago, co-founders Tim Schlidt, Daniel Goldberg, and Tony Eisenberg saw the enormous therapeutic potential psychedelic medicines posed. After years of researching and networking in the space, they co-founded Palo Santo in 2020 to focus on investing across this emerging ecosystem of psychedelic healthcare companies. As a former investment banker and private equity investor active in the life sciences and healthcare services sectors, Tim brings extensive experience evaluating healthcare deals and offers a unique perspective to the nascent sector of psychedelic-focused biopharma

Hosted on Acast. See acast.com/privacy for more information.